Saroglitazar Magnesium is primarily used in the treatment of diabetic dyslipidemia and hypertriglyceridemia. It acts as a dual agonist of peroxisome proliferator-activated receptors (PPAR) alpha and gamma, which helps in regulating lipid and glucose metabolism. This makes it effective in managing lipid abnormalities often associated with type 2 diabetes. By improving lipid profiles and reducing triglyceride levels, it aids in lowering the risk of cardiovascular complications in diabetic patients. Additionally, it has shown potential in addressing non-alcoholic fatty liver disease (NAFLD) by reducing liver fat and improving liver function. Its dual action makes it a versatile therapeutic option for patients with metabolic disorders.